Ingredion Incorporated (INGR) Stock Price & How to Invest

Ingredion Incorporated grinds corn and other crops into starches, sweeteners and texturizing ingredients that end up inside packaged food, beverages, paper and pharmaceuticals. The business reports in three segments: Texture & Healthful Solutions, the global specialty texturant arm that produced ~$627 million of second quarter net sales; Food and Industrial Ingredients in Latin America, at ~$611 million; and Food and Industrial Ingredients in the US and Canada, at ~$488 million. A fourth bucket called All Other holds the PureCircle stevia, sugar reduction and pea protein fortification businesses. Trailing twelve month revenue runs about ~$7.2 billion on a market capitalisation near ~$6.6 billion, and the company has been reshaping the portfolio hard, closing its Cabo plant in Brazil and selling ~51% of its Pakistan subsidiary for ~$165 million in June 2026.

The investment picture in 2026 is two stories running in opposite directions. Specialty volumes are growing and the US commodity segment is not, with US and Canada operating income down ~48% in the first half after a thermal event at the Argo facility in Illinois cost volumes and added manufacturing expense. Meanwhile management agreed in June to buy Tate & Lyle for 595 pence a share in cash, roughly ~£2.7 billion, a deal Tate & Lyle shareholders approved in late July and which is not expected to complete until the second half of 2027. That combination, a depressed commodity year and a large levered acquisition still 12 months from closing, is why the shares trade at a discount to the ingredient companies Ingredion wants to be compared with, and why the reported multiple looks cheaper than the risk profile.

The thermal event at the Argo plant held back volumes and added manufacturing cost through the first half, cutting gross margin to ~23% from ~26% a year earlier and taking US and Canada segment operating income down ~48% year to date. Funding Tate & Lyle takes net debt from roughly ~$0.8 billion today to about ~3.0x EBITDA at completion, and with closing not expected until the second half of 2027 there is a long window of antitrust review, integration planning and carrying cost before any synergy shows up. Second quarter financing costs jumped to ~$55 million mostly because of ~$47 million in hedging losses on the sterling consideration, so the currency exposure is already live even though the deal is not. Latin America supplies roughly a third of sales and carries Mexican peso translation risk plus what management called a more challenging demand environment. High fructose corn syrup consumption in North America is in slow secular decline, which the specialty growth has to outrun rather than merely offset.

6 analysts publish price targets on INGR, averaging $121.50 against a $105.20 price as of August 2026, or +15.5%. The published targets run from $108.00 to $150.00, a moderate spread, and the ratings split 2 buy, 5 hold, 0 sell. Over the last six months there has been 1 raise and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full INGR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ingredion Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Corn costs pass through, so revenue and profit move separately. Bulk sweetener and starch volumes are sold on contracts that pass net corn costs to the customer, which means a fall in corn pulls reported revenue down without necessarily touching gross profit. The most optimistic published target, $150.00, assumes this works close to its best case.

The case against. The thermal event at the Argo plant held back volumes and added manufacturing cost through the first half, cutting gross margin to ~23% from ~26% a year earlier and taking US and Canada segment operating income down ~48% year to date. The most pessimistic target, $108.00, is roughly what INGR is worth if this bites instead.

Read the full bull and bear case on INGR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ingredion Incorporated's investor relations page or your broker.

• Market cap: ~$6.6B
• Revenue (TTM): ~$7.2B
• Net income (TTM): ~$592M
• FY 2026 adjusted EPS guidance: ~$10.30 to ~$10.90
• P/E (trailing / forward): ~11x / ~9.5x
• Net debt (pre acquisition): ~$0.8B

Near ~$105 a share the stock carries about ~11 times trailing earnings and roughly ~9.5 times the midpoint of 2026 adjusted guidance, a visible discount to the branded specialty ingredient houses. That gap prices the commodity half of the business, the Argo disruption and the leverage still to arrive. Reported and adjusted earnings diverge unusually far this year because of the Cabo closure charges, the ~$44 million Pakistan disposal gain and the acquisition hedges, so the ~$9.15 to ~$9.75 reported guide sits well below the ~$10.30 to ~$10.90 adjusted one.

Other names that sit close to INGR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get INGR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so INGR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where INGR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

INGR prices like a commodity processor while spending like a specialty ingredients company, and the next two years decide which description fits.

Whether INGR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is INGR a buy or a sell?, and where the stock could go from here in the INGR stock forecast.

For income investors, whether INGR pays a dividend and how the payout looks is covered in does INGR pay a dividend? And to weigh INGR against a peer, read the full side-by-side comparisons: INGR vs IFF and INGR vs SXT.